Drug Trial Radar · NCT06788444
Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
552
Planned (sponsor's estimate)
Start
Feb 8, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Beijing Tiantan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To explore the efficacy of a single low dose of esketamine for patients with irritable bowel syndrome (IBS).
Conditions
- Irritable Bowel Syndrome
Interventions
The colonoscopyProcedure
Both groups continued to receive the usual standard of gastroenterology care throughout the study period. The patients undergo preoperative preparation according to the requirements of colonoscopy. After entering the endoscopy room, the routine monitoring including electrocardiogram, heart rate, noninvasive blood pressure (BP), respiratory rate, and oxygen saturation (SpO2) are applied for patients. All monitoring data including HR, BP and SpO2 will be recorded at intervals of 3min. Safety assessments will be performed throughout the the research process. As a risk mitigation measure, esketamine should not be administered in patients with systolic blood pressure (SBP) \> 140 mmHg or diastolic blood pressure (DBP) \>90 mmHg prior to administration. After the right upper limb venous access is opened, the patients is placed in the left lateral position. The oxygen mask is placed near the patients' nose and oxygen is provided by the mask for 6L/min during the colonoscopy.
EsketamineDrug
The propofol is administered until the patients loss of consciousness (loss of the eyelash refex). The 0.2 mg/kg esketamine is then administered by the anesthesiologist, but should be discontinued if the SBP ≥200 mmHg or the DBP ≥110 mmHg. After the administration of the 0.2 mg/kg esketamine is completed, the endoscopist will begin the colonoscopic procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The IBS Severity Scoring System (IBS-SSS)Time frame: At baseline and at 3 days, 1 week, 3 weeks, 6 weeks after colonoscopy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.